Shares of Rapport Therapeutics, Inc. (RAPP) surged 5.20% during intraday trading on Wednesday, reflecting significant positive momentum.
The sharp rise appears driven by bullish analyst sentiment, including Wells Fargo raising its price target on the stock from $43 to $46, alongside other positive insights from analysts covering the healthcare sector.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.